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Introduction 37 38
The ability to design and manufacture pharmaceutical dosage forms that are tailored specifically to 39 Alcohol dependence may be described as the physical or psychological obligation for an individual to 136 consume alcohol-containing beverages [13] . The issue is of growing concern in the developed world. 137
For example, alcohol misuse was recorded as the second highest cause for hospital admissions within 138 the United Kingdom (UK) in 2013-2014 [14] . Alcohol dependence may lead to acute and chronic health 139 complications plus place significant strain upon healthcare systems. In the case of the former, 140 individuals may regularly experience depression, anxiety and suffer mild to severe trauma [15] . Over 141 the longer term there is an increased likelihood for the development of cancer, liver disease and the 142 potential for psychological issues to present [16] . 143
Current UK guidelines state that the pattern and severity of alcohol misuse should be initially 144 investigated on an individual patient basis [17] . Here, the aim should be for complete abstinence with 145 the support of an assisted withdrawal programme. Detail of the approach is beyond the remit of this 146 study, however a number of therapeutic interventions can be made to help sustain total abstinence. 147
Within the UK, disulfiram is prescribed to manage alcohol dependence [18] . This agent inhibits the 148 action of acetaldehyde dehydrogenase that is responsible for metabolising alcohol on delivery to the 149 body. The resulting effect leads to an increased concentration of acetaldehyde that causes flushing, 150 increased body temperature and vomiting [19] . Such responses intend to deter the patient from 151 consuming alcohol. Here, the patient must be fully compliant with medical guidance in order to attain 152 the desired treatment outcome (i.e. alcohol abstinence). Thus, a key drawback with the approach is 153 that the patient may consciously decide not to administer the API on a daily basis. One possible route 154 to circumvent this treatment-limiting drawback would be to deliver the API as an implantable device. 155
This study aims to fabricate disulfiram-containing implants via FDM 3D printing and evaluate resulting 156 material properties. Here, we have chosen PLA as the model base material for study as it is 157 biodegradable and biocompatible plus it may facilitate controlled drug release over hours when 158 delivered to the body [2] . Within this work we shall offer comment upon the feasibility of the 159 approach / use of materials, or not, for chronic disease management at the point-of-care. Initially, 280g of PLA feedstock was cut into small fragments of approximately 1-2cm in length. The 180 material was subsequently placed into an oven set at 60°C for two hours to remove adsorbed 181 moisture. Appropriate amounts of API and base were taken and weighed using a five-place analytical 182 balance (A&D, BM-252; California, USA) so as to satisfy a 5% PLA-disulfiram blend. In addition, a 183 sample of the pre-conditioned PLA was taken for use as the placebo. The API and base materials were 184 gradually fed into a Noztek Pro filament extruder (West Sussex, UK) to allow for mixing and drug-185 loaded filament production. With respect to the 5% PLA-disulfiram blend, one batch was extruded at 186 140°C and the other at 170°C. The control sample was extruded at 170°C, with one recirculation phase 187 through the extruder unit. In order to ensure uniform mixing the API-containing extrudate was 188 recycled through the extruder a further time. Upon completion, the filaments were stored in a 189 vacuum desiccator until required for printing in order to guard against moisture adsorption. 190 191
Implant Printing 192 193
The constructs were generated using the Wanhao Duplicator 4 Desktop 3D printer (Wanhao Inc., 194 Florida, USA). The architecture of each dosage form was defined using the SolidWorks® Education 195 Samples of the PLA feedstock, extruded PLA, 5% PLA-disulfiram blend extruded at 140°C and 5% PLA-217 disulfiram blend extruded at 170°C were measured using a digital calliper. In order to quantitatively 218 assess variability along a fixed length of the filaments, a 5cm sample was taken and the width was 219 recorded at 1cm intervals. In addition, photographs of the filaments were taken using a Nikon D60 220 digital single lens reflex camera (Nikon, Japan) with the macro mode selected. from the extruded PLA were placed into a platinum pan. Nitrogen was used as a purge gas with a 264 balance flow rate of 40ml/min and sample flow rate of 60ml/min, the heating rate was 10°C/min 265 starting at room temperature (e.g. 25°C) and the mode was TGA 1000 in a ramp format. Data were 266 collected using QSeries (Q50-1145=TGA Q50) and analysed using Universal Analysis 2000 software (v 267 4.5A). The settings were modified slightly to conduct the thermal analysis of disulfiram to investigate 268 the effect of exposure to temperatures of 170°C for 30 minutes. Here, all parameters remained 269 constant, however the mode was TGA 1000 in a heat and hold format. 270 271 2.2.3.5 Inverse Gas Chromatography Analysis 272
All analyses were carried out using iGC-Surface Energy Analyser (SEA) [21] . The data were analysed 273 using both standard and advanced SEA Analysis Software (Cirrus Plus Analysis Software, v.1.
2.1). 274
Approximately 100-170 mg of the samples were packed into individual iGC silanised glass column, and 275 was run at a series of surface coverage with alkanes and polar probe molecules to determine the 276 dispersive surface energy (S D ) as well as the acid-base free energy of adsorption (ΔGSP). In this study, 277 the sample column was pre-conditioned for 2 hour at 30°C and 0% RH with 10 ml/min helium carrier 278 gas. The experiment was conducted at 30°C with 10 ml/min total flow rate of helium, and using 279 methane for dead volume corrections. 280 
296
The native PLA feedstock ( Figure 3A ) and extruded PLA ( Figure 3B ) presented as white, single filament 297 strands that were able to pass through the head of the FDM 3D printer. On inspection, the extruded 298 PLA was thinner and appeared to demonstrate numerous undulations across the entire length. On 299 the introduction and subsequent blending of disulfiram at 140°C, the filament became discoloured 300 and non-uniform ( Figure 3C ). This observation was more apparent when the material was extruded 301 at the higher operating temperature of 170°C ( Figure 3D ). Here, the outer surface was darker and 302 more irregular in shape. With regard to the implant devices, the dosage form produced using the PLA 303 feedstock presented as a smooth construct ( Figure 3E ) whilst the implant produced from the extruded 304 PLA exhibited distinct layers plus a number of structural defects ( Figure 3F ). 305 306
Filament and Implant Analysis 308 309
In order to investigate the cross-sectional uniformity of the PLA feedstock / extruded filaments digital 310 calliper measurements were taken. Here, a representative sample 5cm length of each material was 311 examined and measurements recorded at 1cm intervals. The data were averaged and recorded in 312 
317
The data presented in Table 1 are supportive of the visual inspections presented above. That is to say, 318 the cross-sectional uniformity of the filaments varied according to the conditions the material was 319 exposed to. As anticipated, the native PLA feedstock demonstrated minimal variation over the 5cm 320 sample length. However, on extrusion the variation increased as demonstrated by the larger standard 321 deviation presented in Table 1 . Once the drug was incorporated into the blend, the variation increased 322 further and the 5% PLA-disulfiram blend extruded at 140°C resulted in an increased diameter by 323 0.72mm than that of the extruded PLA with a three times greater variation along the sample length. 324
The 5% PLA-disulfiram blend extruded at 170°C resulted in even greater variation. 325
On extrusion, this blend was very inconsistent with parts in liquid form and others congregating at the 326 extruder exit in thick bulbous structures. Further to this, when the 5% PLA-disulfiram filament was 327 being extruded at 170°C a noticeable, unpleasant odour was produced suggesting the release of 328 sulphur from degradation of the API (Figure 1) . Subsequently, the mass and measurements of the 3D 329 printed implants were investigated; the data are presented in Table 2 The implants produced using extruded PLA were of lower mass, width, length and volume and 335 generally demonstrated greater variation in these terms when compared to those generated from the 336 native PLA feedstock. As a result of the thinner extrudate diameter (e.g. 1.70mm av., as per Table 1 ) 337 gentle force was required to encourage feed through the FDM 3D printer head. This was so because 338 the rotating feeder heads could not fully grip the extrudate to move it towards the heated printer 339 nozzle. Naturally, such undesirable intervention would have contributed to the varied deposition of 340 layers thus leading to greater variety in mass, width, length and volume measurements. In terms of 341 width and length, the variation within the batches was similar for both PLA feedstock and extruded 342 PLA. Implants printed using the extruded PLA were consistently lighter and smaller than those 343 produced from the PLA feedstock. 344 upon extrusion the surface appeared to become more irregular with a rougher surface ( Figure 5B ). As 363 the drug was incorporated into the blend at the lower operating temperature of 140°C, there was an 364 increase in surface roughness ( Figure 5C ). Furthermore, the irregularity in the filament also became 365 more obvious. Once the temperature was increased to 170°C, the filament surface became 366 considerably smoother however the asymmetrical nature of the strand was more prominent 367 ( Figure 5D ). The images of the implants clearly show the layers that have deposited by the 3D printer 368 in order to produce the construct. The layers forming the implant from the PLA feedstock ( Figure 5E ) 369 appear much sharper and more consistent than those from the extruded strand of PLA ( Figure 5F ). in comparison to the other samples, which had undergone oven drying followed by extrusion, was 425 much more defined. This suggesting that PLA becomes more amorphous once it has been exposed to 426
heat. An exothermic event was displayed between the temperatures of 88.9°C and 106.7°C on all 427 cycles, which could potentially relate to the rearrangement of the polymer chains within PLA matrix. 428
The 5% PLA-disulfiram blends extruded at 140°C and 170°C showed no evidence of the drug melt at 429 72.2°C, but the PLA melt at 166°C was still present. TGA data showed no significant mass loss therefore 430 it can be inferred that disulfiram is dispersed in PLA as a solid solution. 
462
Upon inspection of the data presented in Figure 9 , it is evident that the glass transition peak occurs at 463 a slightly lower temperature of 58°C once the material has been passed through the 3D printer. In 464 addition, the exothermic event for the material occurs at the higher temperature of 106°C. This is 465 the highest temperature of which the exothermic event was observed for all six samples. Moreover, 466 the trace is smoother with less transitions presenting when compared to the native material. 
504
The iGC-SEA data acquired with different solvents is significantly different as shown in Figure 11a and 505 The ability to manufacture tailored pharmaceutical formulations at the point-of-care is an exciting and 548 imminent prospect. Such development may be ascribed to recent advances in both engineering 549 technology (i.e. FDM) and a more detailed understanding of patient pharmacogenomics. Clearly, in 550 order for the strategy to be effective it is imperative to fully understand the interactions between the 551 API(s) of interest and base material(s) and their related manufacturability. To this end, the present 552 study has considered the feasibility of producing API-loaded PLA implants via fused deposition 553 modelling with related materials characterisation. Key recommendations are provided here in order 554
to support future progression within this discipline of pharmaceutics. 555 556
Exemplar Study 557 558
Our current study is based upon that conducted by Water and colleagues in 2015, who effectively 559 loaded a PLA filament with nitrofurantoin to produce a custom feedstock suitable for 3D printing [2] . 560
During the work, the group successfully prepared matrix concentrations of 10%, 20% and 30% 561 nitrofurantoin. Subsequently, the appropriately weighed PLA and API were fed into the extruder 562 screw channel and underwent 2 minutes of recirculation before being ejected as a single strand with 563 an average diameter 1.6±0.1mm. The constructs were designed as disks with pre-determined 564 dimensions of 10mm diameter x 2mm depth and were successfully produced via MakerBot Replicator 565 2 3D printer utilising the custom filament created. Analysis of the construct mass (n=3) indicated that 566 the lower the nitrofurantoin percentage the greater the variation in weight. Furthermore, SEM images 567 of both the extruded filaments and disk constructs confirmed an apparent rougher surface with 568 increased drug loading, which was ascribed to the presence of solid nitrofurantoin within the PLA 569 matrix. This point was further confirmed by x-ray diffraction (XRD) analysis that highlighted 570 nitrofurantoin anhydrate crystals within the disks. 571 572 Thermal analysis demonstrated a single glass transition event at 56.6±0.7°C, a melting point at 574 149.6±0.5°C with no evidence of recrystallisation. Due to the absence of a melting point for 575 nitrofurantoin below 235°C, it was inferred that the PLA-nitrofurantoin blend consisted of two 576 immiscible phases. Drug release profiling was conducted over a period of 45 days. Initially, burst 577 release was observed, within the first three hours, with the highest rate of release for the subsequent 578 two days before steadily decreasing over the remaining period. The degree of drug release correlated 579 to the drug loading (i.e. the greater the drug loading, the greater the rate of drug release). Overall, 580 the approach was deemed as a successful way by which to manufacture drug eluting constructs 581 demonstrating antimicrobial activity. 582 583
Material Characteristics 584 585
Despite applying the approach taken by Water and co-workers, we were unsuccessful in our attempt 586 to manufacture disulfiram-loaded PLA implants to satisfy the personalised medicine paradigm. We 587 attribute the outcome to a number of factors but primarily to API-base incompatibilities at elevated 588 manufacturing temperatures. In order to further the knowledge-base in this sphere of pharmaceutics, 589
we believe that it is important to evaluate the processes undertaken, characterise resultant material 590 properties and provide recommendations going forward. 591
The inherent material incompatibilities led to incongruity in the drug-base filament. This fact in turn 592 resulted in an inability to effectively print because the filament diameter no longer matched the inlet 593 configuration of the 3D printer head. We believe that the diameter of the extruded material is 594 dependent upon a number of factors; primarily the nozzle size dictates the thickness of the produced 595 material however base viscoelastic properties also have an influence. The viscoelastic profile of a 596 material is an essential consideration. The resultant swelling of the PLA on release from the extruder 597 nozzle may be influenced by parameters such as screw speed and extrusion temperature. Although 598 the extruded PLA without API was able to be fed through the printer head, the need for application of 599 pressure to encourage the feed led to inconsistencies in the resulting printed implants. Thermal analysis highlighted further issues with the FDM approach. On consideration of the DSC data 607 presented herein, it is clear that an elevation in operating temperature led to modification to the 608 viscoelastic behaviour of PLA. Furthermore, processing at a temperature of 170°C caused the API to 609 degrade, a point corroborated by the TGA cycle in Figure 6 and the noisy baseline in Figure 8 . 610
However, the TGA cycle for the API in ramp format did not show as significant a weight loss when 611 compared to the isothermal hold. Thus, we infer that API degrades upon exposure to high 612 temperatures over an extended period. The latter point is central to the feasibility of the FDM 613 approach when operating at elevated temperatures at the point-of-care. This is so because the 614 extrusion process typically involves the drug-base blend being exposed to high temperatures for 615 approximately 30 minutes during translocation along the screw thread. 616
We believe that the manufacturing conditions would have led to the degradation of the API within 617 this study resulting in the disagreeable drug-containing filament produced and the unpleasant 618 sulphuric odour. Interestingly, not only does the API appear to be affected by the required conditions, 619 the PLA itself has shown a transition from the feedstock material to the extruded material. An 620 alteration in the polymer composition / arrangement could have contributed to this change in 621 behaviour and consequently the properties of the PLA. Furthermore, the printing process highlighted 622 modifications to the PLA transition characteristics. The high temperature exposure is consistent 623 between both the extrusion and printing processes therefore it is likely to be the leading factor for 624 these variations. Alongside the manufacturing processes themselves, the API appears to have an 625 impact on the PLA. Here, the key transitions were evident (i.e. the glass transition) along with a 626 possible recrystallisation and a melt. However, the extruded PLA being much smoother in terms of its 627 trace could be indicative of the PLA-disulfiram blend being a more crystalline structure. 628
We conclude, therefore, that there is indeed an interaction between disulfiram and PLA. Further to 629 this, the enthalpy of crystallisation was much lower, 1.632 J/g, when disulfiram was incorporated at 630 170°C indicating that less energy was required to encourage this recrystallisation process. Both the 631 blends were notably more brittle upon handling in contrast to the flexible PLA feedstock. The 632 exemplar study did not report any changes in DSC data upon addition of their API. The equipment used during this study (e.g. Noztek Pro Extruder & Wanhao 3D Printer) also 654 contributed to the lack of success. As such, when establishing a laboratory space we recommend that 655 the user considers operational tolerances for all pieces of equipment. Ideally, tolerances should be 656 flexible but within range to allow for slight variation in material properties (e.g. feedstock diameter) 657 that will inevitably arise during the preparative stages. In addition, during the manufacture of blend-658 based pharmaceutical formulations it would seem appropriate to have available a controlled feed to 659 allow the ready addition of the API in a consistent manner plus a recirculation channel to allow 660 effective mixing and minimise material losses. For example, Water and colleagues used a DSM Xplore 661 micro compounder which accommodated two minutes of mixing prior to extrusion [2] . 662 663 664
665
The diameter of the extruder nozzle is a crucial factor to consider for optimal filament generation. 667
Here, the user should ensure that the nozzle is the appropriate size (e.g. 1.75mm) such that the 668 resultant filament will match the inlet configuration of the 3D printer head. However, that being said, 669 the viscoelastic nature of the base polymer, and indeed the drug-base blend, should be borne in mind. 670
On release of the molten material from the nozzle there is potential for the material to swell and bulge 671
[2]. Thus, the resulting variation in the diameter of the feed may be unsuitable for insertion into the 672 3D printer head. One way in which to circumvent this issue is to modify the operating temperature 673
slightly and in such a way account for polymer swelling on release from the extruder nozzle. 674
Additionally, gravitational forces also influenced the diameter of the extruded filament in this study. 675
As the length of the filament increased the weight pulling on the swollen extrudate also increased and 676 the thinner the strand became. Thus, we advocate the use of a lubricated, plate-like structure in 677 proximity to the nozzle to adequately support the extrudate on release from the nozzle to maintain a 678 consistent diameter. 679
The 3D printer employed during this study certainly contributed to the difficulties experienced. The 680 high precision requirement for the filament diameter made the printing process very challenging. If 681 the filament (drug loaded or not) deviated from the diameter of 1.75mm then the feed system would 682 either not detect its presence or clog. We suggest, therefore, that an adjustable clamp inside this 683 mechanism would be beneficial to allow the feed of filaments that may be for instance 1.75mm ± 684 0.1mm. Additionally, improved resolution would provide a smoother, more aesthetically pleasing 685 finish to the dosage forms produced and as such instil greater patient confidence. This is a prime 686 consideration to take into account ahead of purchasing such a unit. Here, we believe that investment 687
in the most precise 3D printer would certainly be beneficial for the formulator over time. 688
The greatest limitation to study success was the incompatibility between the base material and API. 689
We believe that base material selection must be determined by considering four key elements; namely 690 the safety profile of the material, manufacturability (incl. drug-base incompatibilities), drug release 691 characteristics and material degradation over time. As previously stated, PLA is biodegradable and 692 demonstrates a drug release profile covering a number of days, thus making it an ideal material for 693 implantable devices. However, the work presented herein clearly demonstrates that great care must 694 be taken during the manufacturing process. 695 696 697 Clearly, if the API does degrade during the formulation process then it will no longer hold therapeutic 728 value. Accordingly, if we give consideration to the model API employed within this study, in order to 729 ensure activity on delivery to the body we would require formulation with a biodegradable / 730 biocompatible polymer of significantly lower melting point (e.g. 60°C) as compared to the high 731 operating temperatures noted with PLA. In the same manner, a large number of APIs will experience 732 similar deleterious effects at elevated temperatures, which may be exemplified on consideration of 733 the first generation antihistamine promethazine that is commonly used as an antiemetic [32] . Hence, 734
we underscore the fact that great attention is needed to establish the suitability of the operating 735 conditions during the 3D manufacturing process. All materials should be taken on their individual 736 merits at the outset and carefully monitored on combination. 737 
